Microbot Medical Inc. Annual Report - How They Did This Year

I’m breaking down Microbot Medical’s performance to help you understand their business and decide if they fit your investment strategy.

1. What does this company do?

Microbot Medical builds "surgical assistants"—tiny, robotic tools that navigate the body with extreme precision. Their flagship product, the LIBERTY® Endovascular Robotic Surgical System, is a fully disposable robot. Unlike massive, expensive systems that require dedicated rooms, Microbot’s tool is compact, mobile, and remotely controlled. They currently focus on blood vessels outside the heart and brain, with plans to expand into cardiology later. Their "Tip-Drive" technology allows surgeons to navigate catheters remotely, which reduces radiation exposure and improves efficiency.

2. Financial performance

The company is currently in a "burn phase," meaning they spend more than they make. For the year ending December 31, 2025, Microbot reported $0 in revenue because they are not yet selling products. Operating expenses totaled $16.8 million, split between research and administrative costs. By year-end, they held $12.4 million in cash. With a monthly spending rate of $1.2 to $1.4 million, they will need to raise additional capital to fund future operations. As of March 2026, they have 67.2 million shares outstanding.

3. Major wins and challenges

The company is transitioning from a research lab to a commercial business. In 2024, they received FDA clearance for the LIBERTY® system, which validates the platform for clinical use. To fund ongoing operations, the company has historically sold additional shares to the public. While this provides necessary cash, it increases the total share count—which grew by over 25% in the last two years—effectively reducing the ownership percentage of existing shareholders.

4. Key risks

Investing in Microbot is a high-stakes bet on a single technology. Here is what could impact your investment:

• The "All-in" Risk: Their entire business model relies on the success of the LIBERTY® system. If it fails to gain market traction or perform as expected in real-world settings, they have no other commercial products to fall back on.
• Geopolitical Instability: A significant portion of their research and development occurs in Yokneam, Israel. Regional conflict could lead to staff shortages, supply chain disruptions, or facility damage, which would delay their commercial rollout.
• Regulatory & Market Hurdles: Even with FDA clearance, the company must secure insurance coverage and convince hospital systems to adopt the technology. If the system is perceived as too expensive or lacks sufficient reimbursement, adoption will be slow.
• Dilution: Because the company is not yet generating revenue, they will likely issue more shares in the future to cover costs. This will further reduce your ownership percentage and may put downward pressure on the stock price.

5. Future outlook

Microbot is shifting from research to commercial sales. To evaluate their progress, watch for three key milestones: the first human use of the LIBERTY® system, the establishment of a U.S. sales team, and potential partnerships with larger medical device companies. Success hinges on their ability to move from $0 in revenue to consistent sales within major hospital networks.

Investor Takeaway: Microbot Medical is a classic "pre-revenue" play. You are essentially betting on the successful commercialization of a single, innovative product. If you are considering an investment, weigh the potential of their robotic technology against the reality that they will likely need to raise more cash—which could dilute your shares—before they ever turn a profit.